378 related articles for article (PubMed ID: 23429996)
1. EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis.
Talasila KM; Soentgerath A; Euskirchen P; Rosland GV; Wang J; Huszthy PC; Prestegarden L; Skaftnesmo KO; Sakariassen PØ; Eskilsson E; Stieber D; Keunen O; Brekka N; Moen I; Nigro JM; Vintermyr OK; Lund-Johansen M; Niclou S; Mørk SJ; Enger PO; Bjerkvig R; Miletic H
Acta Neuropathol; 2013 May; 125(5):683-98. PubMed ID: 23429996
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.
Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K
Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536
[TBL] [Abstract][Full Text] [Related]
3. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
4. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
Li M; Mukasa A; Inda MM; Zhang J; Chin L; Cavenee W; Furnari F
J Exp Med; 2011 Dec; 208(13):2657-73. PubMed ID: 22162832
[TBL] [Abstract][Full Text] [Related]
5. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
6. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
8. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Yoshida Y; Ozawa T; Yao TW; Shen W; Brown D; Parsa AT; Raizer JJ; Cheng SY; Stegh AH; Mazar AP; Giles FJ; Sarkaria JN; Butowski N; Nicolaides T; James CD
Mol Cancer Ther; 2014 Dec; 13(12):2919-29. PubMed ID: 25313012
[TBL] [Abstract][Full Text] [Related]
9. EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.
Basu D; Bewley AF; Sperry SM; Montone KT; Gimotty PA; Rasanen K; Facompre ND; Weinstein GS; Nakagawa H; Diehl JA; Rustgi AK; Herlyn M
Mol Cancer Ther; 2013 Oct; 12(10):2176-86. PubMed ID: 23939378
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Hobbs J; Nikiforova MN; Fardo DW; Bortoluzzi S; Cieply K; Hamilton RL; Horbinski C
Am J Surg Pathol; 2012 Aug; 36(8):1186-93. PubMed ID: 22472960
[TBL] [Abstract][Full Text] [Related]
11. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
12. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
13. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma.
Katanasaka Y; Kodera Y; Kitamura Y; Morimoto T; Tamura T; Koizumi F
Mol Cancer; 2013 Apr; 12():31. PubMed ID: 23617883
[TBL] [Abstract][Full Text] [Related]
15. Predicting epidermal growth factor receptor gene amplification status in glioblastoma multiforme by quantitative enhancement and necrosis features deriving from conventional magnetic resonance imaging.
Dong F; Zeng Q; Jiang B; Yu X; Wang W; Xu J; Yu J; Li Q; Zhang M
Medicine (Baltimore); 2018 May; 97(21):e10833. PubMed ID: 29794775
[TBL] [Abstract][Full Text] [Related]
16. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
17. Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.
Clark PA; Iida M; Treisman DM; Kalluri H; Ezhilan S; Zorniak M; Wheeler DL; Kuo JS
Neoplasia; 2012 May; 14(5):420-8. PubMed ID: 22745588
[TBL] [Abstract][Full Text] [Related]
18. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
19. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
Figueroa JM; Skog J; Akers J; Li H; Komotar R; Jensen R; Ringel F; Yang I; Kalkanis S; Thompson R; LoGuidice L; Berghoff E; Parsa A; Liau L; Curry W; Cahill D; Bettegowda C; Lang FF; Chiocca EA; Henson J; Kim R; Breakefield X; Chen C; Messer K; Hochberg F; Carter BS
Neuro Oncol; 2017 Oct; 19(11):1494-1502. PubMed ID: 28453784
[TBL] [Abstract][Full Text] [Related]
20. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
